Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
-
Sunderland inflict more derby pain on Newcastle
-
Nepali youth demand release of govt report into deadly September uprising
-
US, Iran trade threats to target infrastructure in Middle East
-
Paris doubles up with super-G victory at World Cup finals
-
Dortmund part ways with sporting director Kehl
-
Russia resumes use of space launch site damaged in accident
-
Cuba scrambles to restore power after new blackout
-
Senegal's Idrissa Gueye ready to 'hand back' AFCON medals
-
New Zealand's Walsh bags fourth world indoor gold
-
Goggia claims first super-G title after victory in Kvitfjell
-
Slovenia votes in tight polls, with conservatives eyeing comeback
-
A herd stop: Train kills 3 rare bison in Poland
-
Vietnam, Russia to sign energy deal: Hanoi
-
American Gumberg triumphs in Hainan for second DP World Tour win
-
South Africa clinch 19-run win over New Zealand in fourth T20
-
Iran threatens Middle East infrastructure after Trump ultimatum
-
French elect mayors in key cities including Paris
-
'They beat us with whips': Sudan RSF detainees tell of horrors in El-Fasher
-
Australia's Hannah Green wins historic third tournament in a row
-
China's premier vows to expand global 'trade pie': state media
-
Belgium commemorates Brussels attacks 10 years on
-
Sri Lanka raises fuel prices by 25 percent as war bites
-
Rights groups fear use of arrest to stifle free speech in Pakistan
-
Iranian missiles sow panic, destruction in Israeli towns
-
Damaged Russian tanker to be towed to Libya: state-owned company
-
Gilgeous-Alexander scores 40, LeBron breaks NBA appearance record
-
Cuba hit by second nationwide blackout in a week
-
BTS draws over 100,000 fans to Seoul comeback concert: label
-
US-China 'Board of Trade' may help ties but experts flag market worries
-
Sinner, defending champ Mensik advance to third round at Miami Open
-
Iran missile strikes wound over 100 in two south Israel towns
-
Shai hits 40 as Thunder win despite NBA melee with four ejected
-
Records shattered as US heatwave moves eastward
-
Iran missiles hit southern Israel, injuring more than 100
-
LeBron James breaks record for most NBA games played
-
'Perfect' PSG sweep past Nice to reclaim top spot in Ligue 1
-
Japan coach says Asian Cup crown 'well-deserved' for inspirational team
-
PSG sweep past Nice to reclaim top spot in Ligue 1
-
Robert Mueller, ex-FBI chief who led Trump-Russia probe, dead at 81
-
Milan move to within five points of Serie A leaders Inter
-
Duplantis masterclass as Kerr and record-setter Ehammer shine
-
Rosenior urges Chelsea to 'forget the noise' after damaging loss
-
Marquez ambushed Di Giannantonio to win Brazil sprint
-
Sweden's Duplantis wins fourth world indoor pole vault title
-
Liverpool, Chelsea slip up in Champions League race
-
WHO sends first overland convoy from emergencies hub to Beirut
-
Everton rub salt in Chelsea wounds as Champions League race tightens
-
Coach Mignoni returns but Toulon crash to Stade Francais
-
Robert Mueller, ex-FBI chief who led Trump-Russia inquiry, dead at 81
-
Sinner and Pegula advance to third round at Miami Open
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025.
ASH Presentation Details:
Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center)
Publication Number: 81
Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
Oral Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
Session Date: Saturday, December 6, 2025
Presentation Time: 10:00 AM - 10:15 AM EST
Location: Orlando Convention Center, W414CD
Presenting Author: Aniket Bankar, MD (Princess Margaret Cancer Centre)
Publication Number: 5588
Title: Comprehensive Analyses of Patient-Reported Outcomes from the Phase 3 VERIFY Study of Rusfertide or Placebo Plus Current Standard of Care for Polycythemia Vera
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
Presenting Author: Joseph Shatzel, MD (Oregon Health & Science University)
Publication Number: 5587
Title: Should Dermatologic Examinations Become Routine Standard of Care in Patients with Polycythemia Vera, Observations from the Phase 3 VERIFY Study Prior to Rusfertide Exposure
Poster Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 8, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
Presenting Author: Naveen Pemmajaru, MD (MD Anderson Cancer Center)
Publication Number: 3810
Title: Long-term Rusfertide Treatment in Polycythemia Vera: Initial Results from the Phase 2
THRIVE Extension Study
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Session Date: Sunday, December 7, 2025
Presentation Time: 6:00 PM - 8:00 PM EST
Location: Orlando Convention Center, Poster Hall (West Halls B3-B4)
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and in the NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company, Inc. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
[email protected]
+1 833 500 0061
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
D.Cunningha--AMWN